Eomesodermin and T-bet mark developmentally distinct human natural killer cells

JCI Insight

Volumn 2, Issue 5, 2017, Pages

  Collins, Amélie ^a   Rothman, Nyanza ^a   Liu, Kang ^a   Reiner, Steven L ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85027176238     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.90063     Document Type: Article

References (32)

1. PrabhuDas M, et al. Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol. 2011;12(3):189–194.
2. Thome JJ, et al. Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues. Nat Med. 2016;22(1):72–77.
3. Thome JJ, Farber DL. Emerging concepts in tissue-resident T cells: lessons from humans. Trends Immunol. 2015;36(7):428–435.
4. Vivier E, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49.
5. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–510.
6. Uksila J, Lassila O, Hirvonen T, Toivanen P. Development of natural killer cell function in the human fetus. J Immunol. 1983;130(1):153–156.
7. Phillips JH, Hori T, Nagler A, Bhat N, Spits H, Lanier LL. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins. J Exp Med. 1992;175(4):1055–1066.
8. Ivarsson MA, et al. Differentiation and functional regulation of human fetal NK cells. J Clin Invest. 2013;123(9):3889–3901.
9. Luevano M, et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73(3):248–257.
10. Dalle JH, et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res. 2005;57(5 Pt 1):649–655.
11. Sundström Y, Nilsson C, Lilja G, Kärre K, Troye-Blomberg M, Berg L. The expression of human natural killer cell receptors in early life. Scand J Immunol. 2007;66(2–3):335–344.
12. Le Garff-Tavernier M, et al. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell. 2010;9(4):527–535.
13. Wang Y, Xu H, Zheng X, Wei H, Sun R, Tian Z. High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol. 2007;4(5):377–382.
14. Eissens DN, et al. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS ONE. 2012;7(2):e30930.
15. Gordon SM, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity. 2012;36(1):55–67.
16. Daussy C, et al. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med. 2014;211(3):563–577.
17. Takeda K, et al. TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood. 2005;105(5):2082–2089.
18. Stegmann KA, et al. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver. Sci Rep. 2016;6:26157.
19. Harmon C, et al. Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver. Eur J Immunol. 2016;46(9):2111–2120.
20. Yu J, Freud AG, Caligiuri MA. Location and cellular stages of natural killer cell development. Trends Immunol. 2013;34(12):573–582.
21. Freud AG, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. JEM. 2006;203(4):1033–433.
22. Freud AG, et al. NKp80 defines a critical step during human natural killer cell development. Cell Rep. 2016;16(2):379–391.
23. dim human NK-cell subsets. Blood. 2010;115(2):274–281.
24. Béziat V, Descours B, Parizot C, Debré P, Vieillard V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One. 2010;5(8):e11966.
25. Hudspeth K, et al. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun. 2016;66:40–50.
26. Lugthart G, et al. Human lymphoid tissues harbor a distinct CD69+CXCR6+ NK cell population. J Immunol. 2016;197(1):78–84.
27. Lieberman J. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol. 2003;3(5):361–370.
28. Grzywacz B, et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006;108(12):3824–3833.
29. Cichocki F, Miller JS. In vitro development of human killer-immunoglobulin receptor-positive NK cells. Methods Mol Biol. 2010;612:15–26.
30. Luetke-Eversloh M, et al. NK cells gain higher IFN-γ competence during terminal differentiation. Eur J Immunol. 2014;44(7):2074–2084.
31. Burt BM, et al. The lytic potential of human liver NK cells is restricted by their limited expression of inhibitory killer Ig-like receptors. J Immunol. 2009;183(3):1789–1796.
32. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol. 2009;27:147–163.